Current approach to diagnostics, treatment and prevention of tuberculosis

Czech version

Authors: Martina Vašáková
Authors‘ workplace: Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
Published in: Vnitř Lék 2017; 63(11): 815-820
Category: Reviews

Overview

Tuberculosis is world-wide spread infectious disease with persistant high incidence, mainly in the densely populated countries with low income. Czech Republic belongs to the countries with highly efficient control of tuberculosis and continuously decreasing incidence of the disease. High-risk population for tuberculosis in the Czech Republic are the homeless people, who together with migrants from the countries with high incidence of tuberculosis represent reservoir of infection for our population. Treatment of tuberculosis is long-term, combined and controlled. Minimal efficious duration of the treatment is 6 moths. The most severe form of tuberculosis is multidrug-resistant tuberculosis (MDR-TB) caused by the strains resistant to basic antituberculous drugs, i.e. rifampicin and isoniasid, the treatment of which lasts 2–3 years. Preventive measures against tuberculosis comprise BCG vaccination in new-born and treatment of latent tuberculous infection in the individuals with risk of development of tuberculosis. Discovery of new drugs and new vaccine against tuberculosis together with financial and material resources designated for systematic search for the patients with tuberculosis and their treatment in the developing countries may enable continuous decrease of incidence of tuberculosis, whilst we can only dream about its fully erradication.

Key words:
diagnosis –⁠ epidemiology –⁠ prevention –⁠ treatment –⁠ tuberculosis

Sources

1. Hershkovitz I, Donoghue HD, Minnikin DE et al. Tuberculosis origin: The Neolitic scenario. Tuberculosis (Edinb) 2015; 95(Suppl 1): S122-S126. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tube.2015.02.021.>.

2. Zatloukal P, Kos S. Tuberkulóza. In: Kolek V et al. Doporučené postupy v pneumologii. Maxdorf: Praha 2013 : 141–163. ISBN 978–80–7345–359–6.

3. Global tuberculosis report 2016. ISBN 9789241565394. Dostupné z WWW: <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1>. [17.8.2017].

4. Kolek V, Kašák V, Vašáková M et al. Pneumologie. 2.ed. Maxdorf: Praha 2014. ISBN 978–80–7345–387–9.

5. Kolek V et al. Doporučené postupy v pneumologii. Maxdorf: Praha 2013. ISBN 978–80–7345–359–6.

6. Horsburgh CR, Barry CE, Lange C. Treatment of tuberculosis. N Engl J Med 2015; 373(22): 2149–2160. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1413919>.

7. Treatment of tuberculosis guidelines. 4th ed. Geneva: World Health Organization (WHO) 2010. ISBN 978 92 4 154783 3. Dostupné z WWW: <http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf>.

8. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Resp J 2011; 37(2): 441–462. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00033010>.

9. Vašáková M et al. Moderní farmakoterapie v pneumologii. Maxdorf: Praha 2013. ISBN 978–80–7345–351–0.

10. Vašáková M. BCG vakcinace v České republice v podmínkách nové vyhlášky 299/2010 Sb., ze dne 25. 10. 2010. Stud Pneumol Phtiseol 2011; 71(1): 28–30.

11. Daňková D, Trnka L, Švandová E. Projekt přerušení BCG vakcinace novorozenců na vybraném území České republiky. Souhrnná zpráva za roky 1986–1993. Stud Pneumol Phtiseol 1995(4); 55 : 281–292.

12. Homolka J. Biologická léčba preparáty blokujícími účinek TNF alfa. In: Kolek V et al. Doporučené postupy v pneumologii. Maxdorf: Praha 2013 : 167–170. ISBN 978–80–7345–359–6.

13. Polcová V, Vašáková M, Valentová Bartáková L. Tuberkulóza a latentní tuberkulózní infekce u transplantací. In: Kolek V et al. Doporučené postupy v pneumologii. Maxdorf: Praha 2013 : 170–176. ISBN 978–80–7345–359–6.